Lumexa Imaging (NASDAQ:LMRI) Updates FY 2026 Earnings Guidance

Lumexa Imaging (NASDAQ:LMRI) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share guidance of 0.710-0.770 for the period, compared to the consensus earnings per share estimate of 0.650. The company issued revenue guidance of $1.0 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Barclays cut their target price on Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating for the company in a research note on Wednesday, May 20th. Weiss Ratings assumed coverage on Lumexa Imaging in a research note on Wednesday, May 13th. They set a “sell (e-)” rating for the company. Finally, Raymond James Financial raised Lumexa Imaging from an “outperform” rating to a “strong-buy” rating and set a $23.00 target price for the company in a research note on Monday, February 9th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Lumexa Imaging has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Lumexa Imaging Trading Down 0.3%

LMRI stock opened at $7.70 on Friday. Lumexa Imaging has a 12-month low of $6.45 and a 12-month high of $19.45. The company has a fifty day moving average price of $9.24.

Insider Activity

In other news, Director Brett Brodnax acquired 35,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The shares were purchased at an average price of $7.25 per share, for a total transaction of $253,750.00. Following the acquisition, the director owned 62,027 shares of the company’s stock, valued at $449,695.75. This represents a 129.50% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Lumexa Imaging

Institutional investors and hedge funds have recently modified their holdings of the company. Barclays PLC purchased a new stake in shares of Lumexa Imaging in the 4th quarter valued at $133,000. Sandia Investment Management LP acquired a new position in Lumexa Imaging during the 4th quarter worth $185,000. Hudson Bay Capital Management LP acquired a new position in Lumexa Imaging during the 4th quarter worth $237,000. Oxford Asset Management LLP acquired a new position in Lumexa Imaging during the 4th quarter worth $670,000. Finally, Burkehill Global Management LP acquired a new position in Lumexa Imaging during the 4th quarter worth $925,000.

About Lumexa Imaging

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).